Immix Biopharma Inc

NASDAQ IMMX

Data sourced from

and

Daily

Download Data

Immix Biopharma Inc Price to Earnings Ratio (P/E) on June 03, 2024: -14.40

Immix Biopharma Inc Price to Earnings Ratio (P/E) is -14.40 on June 03, 2024, a -429.51% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Immix Biopharma Inc 52-week high Price to Earnings Ratio (P/E) is -1.96 on August 17, 2023, which is 86.37% above the current Price to Earnings Ratio (P/E).
Immix Biopharma Inc 52-week low Price to Earnings Ratio (P/E) is -18.61 on May 20, 2024, which is -29.23% below the current Price to Earnings Ratio (P/E).
Immix Biopharma Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -6.84.

NASDAQ: IMMX

Immix Biopharma Inc

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date	Dec. 16, 2021
Location	United States
Headquarters	11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees	14
Sector	Healthcare
Industry	Biotechnology

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Key trends